Canadian Biopharma to Outlicense Pain Drug to South Korean Firm
September 12, 2018 at 04:00 AM EDT
Source: Streetwise Reports 09/12/2018 An Echelon Wealth Partners report discussed the deal terms. In a Sept. 5 research note, analyst Douglas Loe with Echelon Wealth Partners reported that Antibe Therapeutics Inc. (ATE:TSX.V; ATBPG:OTCQX) signed a [...]
